TECENTRIQ

• drugatezolizumab178 co-mentions · 46 sources
• tagApproval176 co-mentions · 44 sources
• companyGenentech Inc88 co-mentions · 44 sources
• drugTECENTRIQ HYBREZA20 co-mentions · 5 sources
• drug(atezolizumab + hyaluronidase (human recombinant))10 co-mentions · 5 sources
• tagOncology5 co-mentions · 2 sources
• companyDana-Farber Cancer Institute Inc1 co-mentions · 1 sources
• tagHepatology1 co-mentions · 1 sources

Trials studying TECENTRIQ

• phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
• phase1An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumorscompletedn=195
• phase2A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanomaactive not recruitingn=30
• phase2LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCCterminatedn=1
• phase2Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancerrecruitingn=48
• phase3A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablationcompletedn=668
• phase1D2C7-IT With Atezolizumab for Recurrent Gliomasactive not recruitingn=18
• phase2A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)recruitingn=170